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Whole sequence of the mitochondrial DNA genome of Kearns Sayre 
Syndrome patients: identification of deletions and variants 
Mitochondria both produce the energy of the cell as ATP via respiration and 
regulate cellular metabolism. Accordingly, any deletion or mutation in the 
mitochondrial DNA (mtDNA) may result in a disease. One of these diseases is 
Kearns Sayre syndrome (KSS), described for the first time in 1958, where 
different large-scale deletions of different sizes and at different positions have 
been reported in the mitochondrial genome of patients with similar clinical 
symptoms. In this study, sequences of the mitochondrial genome of three patients 
with clinic features of KSS were analyzed. Our results revealed the position, 
heteroplasmy percentage, size of deletions, and their haplogroups. Two patients 
contained deletions reported previously and one patient showed a new deletion 
not reported previously. These results display for the first time a systematic 
analysis of mtDNA variants in the whole mtDNA genome of patients with KSS 
to help to understand their association with the disease. 
Keywords: mitochondrial disease; large-scale deletion; heteroplasmy; 
haplogroup; phylogenetic analysis. 
Subject classification code: SCIENTIFIC RESEARCH 
 
1. Introduction 
Mitochondrial diseases result from alterations in either the mitochondrial or nuclear 
genome (Gorman et al. 2015; Chinnery, 2015) due to the close relationship of the 
genomes coding for the proteins that constitute the respiratory chain, which is the main 
source of cellular energy. The human mitochondrial genome is a double-stranded DNA 
molecule (mtDNA) of 16569 bp that encodes 13 subunits of the oxidative 
phosphorylation system and 24 RNAs for intra-mitochondrial protein synthesis 
(Gorman et al. 2016). Most of the estimated 1500 mitochondrial proteins are encoded 
by the nuclear genome (Calvo and Mootha 2015). However, mutations or 
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rearrangements in mtDNA, such as deletions and duplications, disturb multiple organ 
systems, particularly the brain and spinal cord, peripheral nerve, heart, muscle and 
endocrine organs (Wallace, 2015; Stewart and Chinnery 2015).  
There are several mutations, rearrangements, or deletions in the mitochondrial genome 
that cause well-known mitochondrial diseases, such as mitochondrial myopathy, 
encephalopathy, lactic acidosis and stroke-like episodes syndrome (MELAS), 
myoclonic epilepsy with ragged red fibers (MERRF), neurogenic muscle weakness, 
ataxia and retinitis pigmentosa (NARP), Leber hereditary optic neuropathy (LHON), 
Pearson Syndrome, chronic progressive external ophthalmoplegia (CPEO) and Kearns 
Sayre Syndrome (Gorman et al. 2016). Furthermore, different variants have been also 
associated with other diseases such as like Alzheimer and Parkinson (Wu et al. 2018; 
Shoffner et al. 1993; Coskun et al. 2012), cancer (Bai et al. 2007), metabolic syndrome 
(Juo et al. 2010) and diabetes (Jiang et al. 2017). 
Among these diseases, the present study focused on Kearns-Sayre Syndrome 
(KSS) with an onset before 20 years, as defined by the presence of ptosis and/or 
ophthalmoparesis due to mtDNA single large-scale deletion and at least one of the 
following features: retinopathy, ataxia, cardiac conduction defects, hearing loss, short 
stature, cognitive involvement, tremor and cardiomyopathy (Mancuso et al. 2015). 
Since KSS was first reported by Kearns and Sayre in 1958, there have been many 
reports of deletions in the mtDNA at different positions and size among patients (Holt et 
al. 1988; Nelson et al. 1989; Montiel-Sosa et al. 2013). In addition, a direct repeat of 13 
bases flanking a common pathogenic large-scale deletion of 4977 bp within nucleotides 
8470-8482 and 13447-13459 has been identified (Schon et al. 1989; Samuels et al. 
2004). Approximately 60% of mtDNA deletions are flanked by direct repeat sequences 
(class I deletions), 30% are flanked by imperfect repeats (class II deletions) and 10% 
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have no flanking repeats (class III repeats) (Mita et al. 1990; Johns et al. 1989; Samuels 
et al. 2004).  
Whole sequences have not been reported for this mitochondrial disease that may 
give us a clue to explain the mechanisms of KSS origin. Consequently, to contribute to 
the knowledge of mtDNA regulation and the cause of the disease (Carelli and Chan 
2014; Latorre-Pellicer et al. 2016; Kang et al. 2016), the complete mtDNA sequences of 
3 patients were obtained and analyzed. Our results showed the size of the large-scale 
deletions, heteroplasmic percentage, haplotype/haplogroup identification and the 
phylogenetic analysis compared with other representative haplogroups. It is important to 
notice that for first time in this area of research, a systematic analysis of mtDNA 
variants in the whole mtDNA genome of patients with KSS was developed. It is 
expected that this analysis will help to understand the mtDNA variants relationships 
with KSS.  
2. Materials and Methods 
2.1 Clinical information 
Molecular analyses of three unrelated patients with clinical information and the 
diagnosis of KSS are included in this study. The first patient was a 10-year-old girl 
previously reported by our group (Montiel-Sosa et al. 2013). To complete the analysis 
of this patient (KSS-1P), the full sequence was obtained. Unfortunately, this patient 
deceased in 2013. Furthermore, the mtDNA sequence of her mother was also obtained 
and analyzed. The second patient (KSS-2P) was a 19-year-old presenting with diplopia, 
progressive external ophthalmoplegia, palpebral bilateral ptosis and sporadic muscle 
cramps. The third patient (KSS-3P) was 18 years old and had had progressive bilateral 
ptosis palpebral since he was 8 years old, ophthalmoplegia, hearing loss, intolerance of 
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exercise, occasional occipital cephalic pain, weight loss, and decreased visual acuity 
since he was 11 years old; he also has a cardiac pacemaker because he suffers from an 
auricular-ventricular blockade. This study was performed according to an Institutional 
Review Board protocol for research on human subjects at Centro Médico Nacional 
Siglo XXI, IMSS. 
2.2 mtDNA analysis 
After receiving informed consent from the parents, total genomic DNA was extracted 
from 50 mg of frozen biopsied skeletal muscle from each patient using a DNeasy Blood 
and Tissue kit and Handbook (Qiagen, Hilden, Germany). 
2.3 Detection and mapping of mtDNA deletions 
Long-range PCR for mtDNA was performed on the muscle sample using the GeneAmp 
XL PCR kit (PerKin-Elmer, Boston, MA) according to previously described protocols 
(Yakes and VanHouten 1997; Santos et al. 2002). The PCR amplification was 
performed using the long-range PCR enzyme mix (Takara, Shiga, Japan) with the 
“Forward” and “Reverse” primers (Supplementary Table 1). The conditions for PCR 
were an initial denaturation at 95°C for 2 min, followed by 9 cycles of 30 s at 92°C, and 
10 min at 68°C; 19 cycles of 92°C for 40 s, 68°C for 12 min, 72°C for 10 min and 95°C 
for 2 min; an additional 9 cycles of 30 s at 92°C and 10 min at 68°C; and then 19 cycles 
at 92°C for 40 s and 68°C for 12 min; and finally an extension at 72°C for 10 min. 
Products were separated and visualized by electrophoresis on a 0.8% agarose gel with 
ethidium bromide.  
Total genomic DNA (5 g) was digested with the restriction endonuclease Pvu II, 
which cleaves human mtDNA at a single position (nucleotide 2652). The digested DNA 
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was electrophoresed on a 0.7% agarose gel and transferred to nylon membranes. The 
nylon membranes were hybridized with the 16S region of a human mtDNA probe 
labelled with the non-radioactive precursor digoxogenin-UTP (Dig-High Prime, Roche 
catalogue #1585606) by PCR amplification following the manufacturer’s protocol. 
Labelling efficiency was tested using the control labelling kit Dig-labelled control DNA 
from Roche. The deleted mtDNA was mapped by long-range PCR of the whole mtDNA 
genome (Tengan and Moraes 1996), which allowed us to determine both the best 
primers to use to amplify the sequence that contained the deleted region and the exact 
limits of this deletion by sequencing. The measurement of the percentage of deletion 
was calculated from the signal intensities of the deletion mutant and the full-length 
molecules using densitometry (Edris et al. 1994).  
After identifying mtDNA deletions in the sample of each patient, the 
amplification of fragments around nucleotides 8470 to 13447 of 7158 bp size was 
examined using the primers L7148(nt.7148) and L14268(nt.14268) to determine if the 
genome of both patients contained the common deletion. Next, the whole mtDNA in 
two fragments was amplified using two pairs of primers, L644/H8982 and L8789/H877 
(Supplementary Table 1), which provided two overlapping fragments of 8381 and 8703 
bp, respectively. This strategy also permitted an approximation of both the localization 
and, by sequencing, the exact sites of the deletion.  
2.4 Sequencing of whole mtDNA  
The whole mtDNA of all samples was amplified and sequenced by using 24 pairs of 
primers previously described (Rieder et al. 1998), with the following PCR conditions: 3 
min at 95°C for an initial denaturation and 35 cycles of 95°C for 30 s, 60°C for 45 s, 
72°C for 55 s, and a final extension at 72°C for 5 min. The 24 overlapping fragments 
were visualized by electrophoresis on a 0.7% agarose gel and purified with ExoSap-IT 
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before the sequencing reaction with the BigDye Terminator v3.1 Cycle Sequencing 
Ready Reaction kit, following the manufacturer´s instructions (Applied Biosystems). 
The products of this reaction were purified and analyzed on an Applied Biosystems 
3730 DNA Analyzer (Applied Biosystems, Foster City, CA, USA). Comprehensive 
contig assembly and sequence alignment was performed using the Sequencher Software 
version 4.1 (Gene Codes Corporation, New York City), and SNPs relative to the revised 
Cambridge Reference Sequence (rCRS) were scored and confirmed by manual checking 
of electropherograms. 
2.5 Mutation impact analysis 
The impact of the non-synonym mutations was assessed by using the predictors 
MitImpact 2.9 (Castellana et al. 2015; http://mitimpact.css-mendel.it/), Polymorphism 
Phenotyping (PolyPhen v2; Adzhubei et al. 2010), and MutationAssessor (Reva et al. 
2011). MitImpact provided a view of the pre-computed pathogenicity score of the 
amino acid change as a pathogenic predictor; PolyPhen predicted the potential impact of 
the amino acid substitution in the protein structure and function by using physical and 
comparative considerations; and MutationAssessor predicted the functional effect due to 
amino acid substitution in the protein based on evolutionary conservation. 
2.6 Phylogenetic analysis 
Sequences of the patients of this study were aligned with 51 and 84 representative 
Amerindian and Asian mtDNA complete sequences of haplogroups B (KSS-P2) and C 
(KSS-P1 and KSS-P3), respectively, using the Clustal W program (Thompson et al. 
1994). The phylogenetic tree was then constructed using maximum likelihood 
reconstruction, the Neighbor Joining algorithm (Nei et al. 1985), and the HKY85 
nucleotide substitution model (Hasegawa et al. 1985). The TN93RV algorithm included 
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8 
in the Hypothesis Testing using Phylogenies software package was used to obtain the 
genetic distance with gamma correction 1 (Tamura and Nei, 1993) (HyPhy, Pond et al. 
2005). Finally, a bootstrap of 1000 repetitions was performed. 
3. Results 
3.1 Clinical features of patients 
Kearns-Sayre Syndrome is a mitochondriopathy with an onset of symptoms before 20 
years of age. Accordingly, the three unrelated patients reported here presented with 
palpebral bilateral ptosis, progressive external ophthalmoplegia and cardiomyopathy. In 
addition, patient KSS-P2 had sporadic muscle cramps, and patient KSS-P3 suffered 
from left hearing decreases, fatigue on exercise, occasional occipital headaches, weight 
loss and progressive decreases in visual acuity. 
3.2 Identification of mtDNA deletion  
To identify the size and location of the deletions in the mitochondrial genome of KSS, 
long PCR amplification, southern blot assays (Figure 1A) and sequencing (Figure 1B-
D) were performed. The large-scale deletion of 7629 bp from nucleotides 7437 to 15065 
of the mtDNA (Figure 1B) of KSS-P1 was reported previously (Montiel-Sosa et al. 
2013). Sequence analysis showed that the mother and her daughter had the same full 
sequence; however, the patient's mother did not show the large-scale deletion. 
The amplification of the whole mtDNA of KSS-P2 and KSS-P3 by long-range 
PCR and southern blot analysis showed two bands of approximately 16.5 and 11.2 Kb, 
indicating the presence of a heteroplasmic deletion of approximately 5 Kb in each 
patient (Figure 1A). Then, to determine if the patients displayed a common large-scale 
deletion, the mtDNA was amplified using the primers displayed in Supplementary 
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Table 1. KSS-P2 showed a deletion between nucleotides 7148 and 14268 because the 
amplicon obtained was 2100 bp instead of 7158 bp. Digestion of this fragment with 
Hinc II restriction endonuclease displayed the expected two bands of 630 and 709 bp, 
indicating that enzyme cuts at nucleotides positions 7857 and 13638 were present. 
Primers from nucleotide 8150 to 13650 were used to obtain an expected amplicon of 
5500 bp; however, we obtained a fragment of 500 bp. The sequence of this fragment 
revealed that the deletion starts at nucleotide position 8469 and ends at 13446, 
indicating a deletion of 4977 bp. KSS-P2 contained a large-scale deletion flanked by a 
perfect direct repeated of 13 bp, which was reported previously as flanking the common 
deletion (Samuels et al. 2004). The genes deleted in KSS-P2 are ATPase 6 and 8, COIII, 
tRNAG, ND3, tRNAR, ND4, tRNAH, tRNAS, tRNAL and part of ND5 (Figure 1C). 
The mtDNA of KSS-P3 was amplified using two pairs of primers L644/H8982 
and L8789/H877 (Supplementary Table 1) to obtain two overlapping fragments of 8381 
and 8703 bp, respectively. The fragments obtained were 8381 bp and 3100 bp, which 
correspond to a large-scale deletion of 5387 nucleotides. To map the location of this 
deletion, the 3100 bp was digested with the restriction enzymes as follows: Pst I, Apa I, 
Hinc II, Xba I, Bam HI, and Xho I, with the restriction sites at positions determined by 
NEBcutter V2.0 (Vincze et al. 2003, http://nc2.neb.com/NEBcutter2/) in a fragment 
from nucleotides 7148-877. Pst I, Apa I, Xba I, and Hinc II cut at nucleotide sites 9024, 
9269, 10256, 10016, 16458, indicating the absence of the restriction sites at positions 
12409, 13262, 13637, 14,259, and 14956 and, therefore, the lack of a region that 
contains these sites. To continue mapping the deletion, a region between nt 9989 and 
15978 was amplified, obtaining an amplicon of 600 bp that was sequenced, which 
established that the deletion involved nucleotides 10371 to 15758. This result indicated 
a deletion of 5387 bp (Figure 1D). The sequence of KSS-P3 had no flanking repeated 
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bases. The genes deleted in KSS-P3 were tRNAR, ND4, tRNAH, tRNAS, tRNAL, ND5, 
ND6 and part of cyt b (Figure 1D). 
Quantification of heteroplasmic mtDNA deletions using densitometry was 84%, 
40%, and 60% for KSS-P1 (Montiel-Sosa et al. 2013), KSS-P2, and KSS-P3, 
respectively.  
3.3 Analysis of whole genome sequence 
To search for common variants relevant to the pathology and identification of 
haplogroups, whole mitochondrial genome sequencing of KSS-P1, KSS-P2, and KSS-
P3 was determined, and the GenBank numbers are MG652750, MG652752 and 
MG652751, respectively. Table 1 shows all of the polymorphisms identified in the three 
sequences of the patients. Sequences of KSS-P1, KSS-P2, and KSS-P3 displayed 28 
synonym variants (Table 2) and a total of 7 non-synonym changes for each one (Table 
3). Among these, m.6340CT has been associated with cancer (Scott et al., 2012); 
m.7444GA has been reported to be associated with Leber's hereditary optic neuropathy 
(LHON; Yuan et al. 2005) and sensorineural hearing loss (SNHL; Yang et al. 2016); 
and m.10398AG has been related to Parkinson's disease (PD; Otaegui et al. 2004), 
altered mitochondrial matrix pH (Kazuno et al. 2006), metabolic syndrome (Juo et al. 
2010) and has been considered a risk factor for breast cancer (Bai et al. 2007). 
3.4 Haplogroup identification  
Haplogroups of the KSS patients were determined to define whether they have any 
relevance to this disease because mitochondrial haplogroups have been reported to be 
associated with other diseases such as Alzheimer and breast cancer, (Santoro et al. 
2010; Ma et al. 2018 respectively), or influence the mitochondrial function (Kenney et 
al. 2014). Consequently, haplogroups for each patient were identified according to 
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Achilli et al. 2008, Derenko et al. 2010, Kumar et al. 2011, Rieux et al. 2014 and 
MitoMaster (Brandon et al. 2009; http://www.mitomap.org). The KSS patient 1 and her 
mother were haplogroup C1b14, KSS-P2 was haplogroup B2 and patient KSS-P3 was 
haplogroup C1d. Variants m.3552TA, m11914GA and m.16327CT specific for 
haplogroup C were common in KSS-P1 and KSS-P3. Polymorphisms m.493AG, 
m.5894AG, m.10397AG and m.16181AG were specific for C1b14 (Table 1) and 
exclusively found in KSS-P1 and her mother; and m.194CT, m.6340CT, 
m.9545AG, m.13263AG, m.16051AG and m.16325TC variants (Table 1) were 
specific for haplogroup C1d, as observed in KSS-P3. The haplogroup B2 of KSS-P2 
was defined by the presence of variants m.827AG, m.3547AG, m.4820GA, 
m.4977TC, m.6473CT, m.9950TC, m.11177CT, m.13590GA, m.15535CT, 
m.16217TC, and the deletion of 9 bp at nucleotide positions 8281-8289 (Table 1). 
3.5 Phylogenetic analysis 
The phylogenetic tree of the KSS patients was constructed directly from the entire 
mtDNA sequences and representative sequences obtained from GenBank to understand 
the genetic ancestry through the direct maternal line. Figures 2-3 show the phylogenetic 
tree of the 3 mtDNA sequences from the KSS patients (deposited in GenBank under 
Accession No. MG652750 - MG652752). According to the analysis of variants obtained 
by MitoMaster (Brandon et al. 2009; Lott et al. 2013) and previous haplogroup 
classifications (Kumar et al. 2011), the mtDNA phylogenetic trees of KSS-P1, KSS-P3 
and KSS-P2 displayed haplogroups C1b14, C1d (Figure 2)  and B2 (Figure 3), 
respectively. 
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4. Discussion 
An in depth genetic characterization of whole mtDNA genome was carried out 
in this research, which will help to understand pathogenic mechanisms of mtDNA 
diseases like KSS. Previous research have shown that a better understanding of the  
location, length and percentage of a single mtDNA deletion explains mitochondrial 
syndromes (López-Gallardo et al. 2009; Grady et al. 2014; Mancuso et al. 2015; Rocha 
et al. 2018). The effect of mtDNA population genetic variation might be very important 
in patients with single mtDNA deletions. Because, it is well known that mtDNA genetic 
background can affect mitochondrial gene expression, disease susceptibility and 
severity of disease-causing mtDNA mutations (Wallace. 2015; Cohen et al. 2016; Wei 
et al. 2017). Thus, these findings will support future meta-analyses in order to refine the 
association between single mtDNA deletions and mitochondrial syndromes. 
Mitochondrial diseases have been continuously studied because of their 
complicated diagnosis and treatment. Kearns Sayre Syndrome is associated with large-
scale mtDNA deletions that differ among patients. It is important to extend the sequence 
analysis beyond the large-scale deletion and the flanking regions to find and establish 
haplogroup-related and mitochondrial pathogenic variants. Recently, Latorre-Pellicer et 
al. (2016) used conplastic animals to reveal that mitochondrial variations have an 
important influence on the physiology, phenotype and longevity of organisms, 
suggesting that the same effect occurs in humans.  
Importantly, it also has been demonstrated by using cybrid cells that mtDNA 
haplogroup J has increased transcription and replication and, as a result, there are more 
mtDNA molecules in haplogroup J than there are in haplogroup H (Suissa et al. 2009). 
Therefore, mitochondrial haplogroups of patients with mitochondrial disorders could be 
very relevant. Consequently, it is very important to determine the mtDNA haplogroups 
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when treating mitochondrial diseases, e.g., with mitochondrial replacement therapy in 
human oocytes (Latorre-Pellicer et al. 2016).   
Whole mtDNA sequences in patients displayed twelve non-synonym changes 
(Table 3); among them, m.8584GA, m.8701AG, and m.14318TC were shared 
between KSS-P1 and KSS-P3, and m.8860AG, m.14766CT, and m.15326AG were 
shared among the 3 patients. All of these non-synonyms changes were previously 
reported in MITOMAP (http://www.mitomap.org). Some of these variants have been 
associated with other disease conditions (Rollins et al. 2009; Ebner et al. 2011; Bai et 
al.2007; Tommasi et al. 2014; Rad et al. 2016; Venkatesan et al.2014; Wallace. 2015) 
such as a) m.6340CT and m.7444GA variants in CO1 gene identified in the KSS-P3 
and KSS-P2 patients respectively, which were previously detected in patients that 
suffered prostate cancer (Petros et al. 2005; Scott et al. 2012), Leber's hereditary optic 
neuropathy (LHON), or sensorineural hearing loss (SNHL) (Zhu et al. 2006; Yang et al. 
2016); b) m.827A>G variant located at the A-site of the mitochondrial 12S rRNA gene 
identified in KSS-P2 patient, these were previously associated with non-syndromic and 
aminoglycoside-induced hearing loss (Li et al. 2004; Xing et al. 2006), a sign in KSS 
patients, probably due to alteration of the rRNA structure leading to mitochondrial 
dysfunction (Chaig et al. 2008; Xing et al. 2006; Nivoloni et al. 2010; Barbarino et al. 
2016); and c) m.10398AG variant within the ND3 gene identified in KSS-P1 and 
KSS-P3 has been identified as a risk factor with the metabolic syndrome (Juo et al. 
2010), and it is considered a predictor for T2D, which is present in some of the KSS 
patients (Ho et al. 2014). In addition, since 153A>G and 152T>C variants are located 
close to the replication site in KSS-P1 and KSS-P3 respectively, it would be important 
to study their function in cybrids, since it has been reported that m.150C>T variant 
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close to the replication site changes the replication site in the mtDNA (Chen et al. 
2012). 
Kazuno et al. (2006, 2008) found in cybrid cell lines that mitochondrial 
metabolism can be altered by m.8701G/10398G variants identified in the mtDNA 
deleted region of KSS-P1 and KSS-P3 patients, which has been reported to play a role 
in the pathophysiology of complex diseases by affecting mitochondrial matrix pH and 
intracellular calcium dynamics. Cybrids with 10398G and 8701G variants did not 
respond to treatment with valproate to stabilize calcium levels; contrary cybrids with 
10398A and 8701A variants responded to the treatment (Kazuno et al. 2008). These 
differences are important since the KSS-P2 patient had 8701A/10398A variants, which 
make the patient susceptible to some kind of medical treatments and KSS-P1 and KSS-
P3 patients containing m.8701G/10398G variants will be resistant to the treatment of 
some compounds. Some KSS patients may present cyclic vomiting syndrome (Boles et 
al. 2007), previously associated with the variant m.16519T (Venkatesan et al.2014; 
Boles et al. 2010) identified in KSS-P1 and KSS-P2. Accordingly, the treatment for 
these patients usually include mitochondrial supplements like co-enzyme Q10, 
riboflavin and L-carnitine (Boles et al. 2007). These findings highlight the importance 
of mitochondrial genetic background that also may influence the patient response to 
medical treatments. 
Haplogroup identification was also developed because variants in the whole 
mtDNA genome primarily define haplogroup, which has been found to be associated 
with certain human diseases (Wu et al, 2018). KSS-P1 and her mother belonged to the 
C1b14 haplogroup (Figure 2), which is uncommon, and there are only thre sequences 
reported in the database of mtDNA sequences (GenBank). One of them pertained to a 
Zapotec individual (GenBank number: KJ923846), and the other was from a Mexican 
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American individual (GenBank number: HQ012208) (Gómez-Carballa et al. 2015, 
Kumar et al. 2011). There is also one sequence with the C1b14 haplogroup from the 
1000 genomes project (NA19773). Furthermore, there is a partial sequence reported in a 
pre-Hispanic Mayan individual that belongs to the C1b14 haplogroup (Ochoa-Lugo et 
al. 2016). This haplogroup was confirmed by the phylogenetic analysis displayed in 
Figure 2. Haplogroups C1b, C1c and C1d are of Beringian origin, as are the 
haplogroups A2, B2 and D1 (Achilli et al. 2008). The estimated age of the C1b14 on the 
American continent is approximately 15 ky (Gómez-Carballa et al. 2015). Moreover, 
one infant burial (USR1) from a common interment at the Upward Sun River Site in 
central Alaska dating to ~11,500 cal B.P. was determined to possess variants that define 
mitochondrial lineage C1b (Tackney et al. 2015). The presence of the C1b14 
haplogroup in a Mayan ancient individual clearly shows that this haplogroup was 
present in Mexican pre-Hispanic populations, and it has been maintained in 
contemporary Mexican populations such as the Zapotec, although in very low 
frequencies suggesting that this haplogroup has not been expanded in contemporary 
populations successfully. 
The KSS-P3 displayed haplogroup C1d (Figure2), which is a founding Native 
American lineage that is defined by transitions at nucleotides 194 and 16051 and 
entered the continent from Beringia at the end of the Last Glacial Maximum (18.7±1.4 
kya) (Achilli et al. 2008; Perego et al. 2010). The C1d haplogroup is distributed along 
the American continent (Perego et al. 2010) and has been identified in a Mexican 
mestizo population with a frequency of 18.8% in a cohort of 270 individuals 
(Guardado-Estrada et al. 2009). KSS-P3 sequence was grouped with sequences from 
Mexican individuals living in USA (Figure 2).  
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Finally, KSS-P2 belongs to haplogroup B2 of a Native American ancient 
haplogroup, with coalescence time estimated at 19 ky (Achilli et al. 2008). This lineage 
was also identified in one infant burial (USR2) from a common interment at the Upward 
Sun River Site in central Alaska dating to ~11,500 cal B.P. (Tackney et al. 2015). In 
addition, this haplogroup has been associated with a risk of cervical cancer in a Mexican 
mestizo population (Guardado et al. 2012), but it is not associated with prostate cancer 
in Colombian patients (Cano et al. 2014). There is also one MELAS case of a Mexican 
patient reported with haplogroup B2c (Delgado-Sanchez et al. 2007).  
The MXKSS-P2 sequence is more closely related to the sequences with 
haplogroups B2u and B2k, with very low frequency in Mexican American individual 
residents of the USA (Figure 3). The B2o1 haplogroup is also in the same branch and 
corresponds to sequences from Bolivian and Colombian individuals. The MXKSS-P2 
sequence is more closely associated with haplogroup B2u and is a rare haplogroup in 
Mexico because no identical sequences have been reported in the mitochondrial 
databases.  
The haplogroup of patients with mitochondrial diseases in Mexicans has rarely 
been reported in Mexican populations. Therefore, it is recommended to sequence and 
determine both the haplogroup and haplotype to establish their importance for 
pathology and to trace the migration and evolution of populations. Two of the KSS 
patients reported in this study belong to haplogroup C, and one belongs to haplogroup 
B; the latter has been associated with susceptibility to diseases such as hearing loss 
(Ying et al. 2015), Alzheimer’s disease (Bi et al. 2015), high-altitude pulmonary edema 
(Luo et al. 2012) and T2D (Liou et al.2012). 
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5. Conclusions  
Our results support the importance of performing full sequencing of mitochondrial 
genomes of patients with multisystem disorders to discover new variants and their 
functional impact as part of complex protein suppliers of ATP by the phosphorylation 
system. Furthermore, the three patients have different classes, positions, lengths and 
grades of heteroplasmy of the large-scale deletion, suggesting that size and 
heteroplasmy are related to the grade of this pathology. We can also suggest that when a 
family has any family history of mitochondrial disease, it is important to perform full 
mtDNA sequencing to diagnose any mutation associated with the disease and suggest 
an effective treatment or a preventative strategy with a mitochondrial replacement 
procedure. 
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Figure Legends 
Figure 1. Characterization of the mtDNA deletion. (A) Southern blot analysis of 
mtDNA from KSS-P2 and KSS-
Hind III; lines 2 and 5 display the long range PCR from KSS-P2 and KSS-P3 showing 
the 16.5 kb bands with no deletion and the DNA containing the large deletions of 
approximately 11.2 kb for KSS-P2 and KSS-P3, respectively; line 4 corresponds to a 
control mtDNA with no deletion; sequence across the mtDNA deletions breakpoint 
showing the site of the flanking sequence in (B) KSS-P1 reported previously (Montiel et 
al. 2013) and (C and D) KSS-P2 and KSS-P3, respectively. 
 
Figure 2. Molecular phylogenetic analysis by the maximum likelihood method of 
haplogroup C. The evolutionary history was inferred by using the maximum likelihood 
method based on the Hasegawa-Kishino-Yano model (Hasegawa et al. 1985). The tree 
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with the highest log likelihood (-24486.9906) is shown and Akaike’s informative 
criterion (49750.9). The percentage of trees in which the associated taxa clustered 
together is shown next to the branches. Initial tree(s) for the heuristic search were 
obtained automatically by applying Neighbor-Join and BioNJ algorithms to a matrix of 
pairwise distances estimated using the maximum composite likelihood (MCL) 
approach, and then selecting the topology with the superior log likelihood value. A 
discrete gamma distribution was used to model evolutionary rate differences among 
sites (3 categories (+G, parameter = 0.0500)). The rate variation model allowed for 
Tamura and Nei. The tree is drawn to scale, with branch lengths measured in the 
number of substitutions per site. The analysis involved 76 nucleotide sequences (Supp. 
Table 2). All positions containing gaps and missing data were eliminated. There were a 
total of 16,560 positions in the final dataset. The bootstrap = 1000. Sequences in bold 
are from the KSS patients, and the ancient sequences are labeled with an asterisk (*).  
 
Figure 3. Molecular phylogenetic analysis by the maximum likelihood method of 
haplogroup B. The evolutionary history was inferred by using the maximum likelihood 
method based on the Hasegawa-Kishino-Yano model (Hasegawa et al. 1985). The tree 
with the highest log likelihood (-24486.9906) is shown with Akaike’s informative 
criterion (49750.9). The percentage of trees in which the associated taxa clustered 
together is shown next to the branches. Initial tree(s) for the heuristic search were 
obtained automatically by applying Neighbor-Join and BioNJ algorithms to a matrix of 
pairwise distances estimated using the maximum composite likelihood (MCL) 
approach, and then selecting the topology with the superior log likelihood value. A 
discrete gamma distribution was used to model evolutionary rate differences among 
sites (3 categories (+G, parameter = 0.0500)). The rate variation model allowed for 
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Tamura and Nei (Tamura and Nei. 1993). The tree is drawn to scale, with branch 
lengths measured in the number of substitutions per site. The analysis involved 76 
nucleotide sequences (Supp. Table 2). All positions containing gaps and missing data 
were eliminated. There were a total of 16,560 positions in the final dataset. The 
bootstrap = 1000. Sequences in bold are from the KSS patients, and the ancient 
sequences are labeled with an asterisk. 
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Table 1. Mitochondrial genetic variants of KSS patients. 
 
 
 
 
 
 
 
Variants from nucleotides 10,000 and below, variants from nucleotides 10,000 to 16,569. Variants related to haplogroup designation are 
shown in bold. *Patient KSS-P2 with haplogroup B also has a 9 bp deletion from nucleotides 8281 to 8289. 
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Table 2. Synonym variants identified in the KSS patients and the mother of KSS-1P. Analysis was performed by MitoMaster. 
Nuleotide 
position 
KSS 
patient* 
Locus Mutation 
type 
Amino acid Codon 
position 
GB 
frequency % 
T3552A 1, 3 MT-ND1 transversion Ala82 Third  3.24 
G3915A 2 MT-ND1 Transition  Gly203 Third 1.34 
A4715G 1, 3 MT-ND2 Transition  Gly82 Third 3.92 
A4769G 1, 2, 3 MT-ND2 Transition  Met100 Third 97.26 
A5894G 1 MT-NC5 Transition  Non-coding - 0.35 
C7028T 1, 2, 3 MT-COI Transition  Ala375 Third  78.89 
C7196A 1, 3 MT-COI Transversion Leu431 Third 3.83 
T7885C 2 MT-COII Transition  Ile100 Third 0.03 
T9540C 1, 3 MT- 
COIII 
Transition  Leu112 First 32.92 
A9545G 1, 3 MT- 
COIII 
Transition  Gly113 Third  4.00 
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T9950C 2 MT-
COIII 
Transition  Val248 Third 2.86 
A10397G 1 MT-ND3 Transition Trp113 Third 0.93 
C10400T 1, 3 MT-ND3 Transition Thr114 Third 20.42 
G10646A 3 MT-
ND4L 
Transition Val59 Third 0.33 
T10873C 1, 3 MT-ND4 Transition  Pro38 Third 32.88 
G11719A 1, 2, 3 MT-ND4 Transition Gly320 Third 75.36 
G11914A 1, 3 MT-ND4 Transition  Thr385 Third 11.02 
G12007A 2 MT-ND4 Transition  Trp416 Third 6.48 
A12172G 3 MT-TH Transition  tRNA p38 Anticodon 
loop 
0.78 
C12705T 1, 3 MT-ND5 Transition Ile123  Third 41.74 
T13174C 2 MT-ND5 Transition  Leu280 First 0.08 
A13263G 1, 3 MT-ND5 Transition  Gln309 Third 3.47 
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G13590A 2 MT-ND5 Transition  Leu418 Third 5.39 
T14783C 1, 3 MT-CYB Transition Leu13 First 20.29 
G15043A 1, 3 MT-CYB Transition Gly99 Third 22.77 
G15301A 1, 3 MT-CYB Transition Leu185 Third 27.55 
A15487T 1, 3 MT-CYB Transversion Pro247 Third 3.85 
C15535T 2 MT-CYB Transition  Asn263 Third 2.01 
*KSS patient 1, 2, and 3 represent patient KSS-P1, KSS-P2, and KSS-P3 respectively. KSS-P1M has the same synonyms variants as KSS-P1. 
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Nucleotid
e position 
KSS 
Patient 
Locus Amino acid PolyPhe
n 
Mutation 
Assessor 
Impact 
Codon 
positio
n 
GB 
frequency 
(%) 
Disease reported Reference 
A3547G 2 MT-ND1 I81V Benign Low First 1.44   
C6340T 3 MT-CO1 T146I Benign Medium Second  0.16 Prostate cancer  Scott et al., 2012 
G7269A 2 MT-CO1 V456M Benign Neutral First 0.16   
G7444A 2 MT-CO1 TERM514K - - Second  0.37 LHON, SNHL, 
DEAF 
Gorman et al. 
2016 
G8584A 1 and 3 MT-
ATP6 
A20T Benign Neutral First  4.64   
A8701G 1 and 3 MT-
ATP6 
T59A Benign Neutral First  32.82   
A8860G 1, 2 and 
3 
MT-
ATP6 
T112A Benign Medium First 98.34   
A10398G 1 MT-ND3 T114A Benign Neutral First 43.68 PD, longevity, Otaegui et al. 
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Table 3. Analysis of nonsynonymous variants identified in the KSS patients and the mother of patient 1 by PolyPhen and MutationAssessor 
programs. Predicting functional effect analysis in MitImpact 2.9 in the 4 whole sequences of this study by PolyPhen and MutationAssessor for 
pathogenicity predictions. 
PD: Parkinson's disease. 
altered 
mitochondrial pH, 
metabolic 
syndrome, breast 
cancer risk 
2004; Dato et al. 
2004; Kazuno et 
al. 2006; Juo et al. 
2010; Bai et al. 
2007 respectively 
C11177T 2 MT-ND4 P140S Benign Medium First 1.44   
T14318C 1 and 3 MT-ND6 N119S Benign Neutral Second 3.27   
C14766T 1, 2 and 
3 
MT-
CYB 
T7I Benign NA Second 75.1 5   
A15326G 1, 2 and 
3 
MT-
CYB 
T194A Benign Neutral First 98.29   
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Abbreviation List 
ATP: Adenosine triphosphate 
KSS: Kearns Sayre syndrome 
mtDNA: mitochondrial DNA 
MELAS: Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes syndrome  
MERRF: Myoclonic epilepsy with ragged red fibers 
NARP: Neurogenic muscle weakness, ataxia and retinitis pigmentosa 
LHON: Leber hereditary optic neuropathy  
CPEO: Chronic progressive external ophthalmoplegia 
KSS-1P: First patient  
KSS-2P: Second patient  
KSS-3P: Third patient  
bp: base pair 
nt: nucleotide 
SNP: Single nucleotide polymorphism 
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rCRS: Revised Cambridge Reference Sequence 
PD: Parkinson's disease 
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Research Highlights: 
1. Mitochondrial DNA genome of Kearns Sayre Syndrome patients displayed haplogroups with low frequency in contemporary populations. 
2. Two patients contained deletions reported previously and one patient showed a novel deletion not reported previously. 
3. Mitochondrial DNA polymorphism were displayed in other diseases.  
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